**Introduction:** Gout is a common cause of inflammatory arthritis affecting approximately 2.5% of the UK population. Attacks of gout are very painful and can cause erosive damage to joints. It is therefore important to treat attacks promptly and offer prophylaxis to prevent further attacks from occurring. An updated British Society for Rheumatology guideline for the management of gout was released in 2017. Nonetheless, managing these patients can still be challenging. We describe a patient with resistant gout who was unable to swallow tablets or capsules.

**Case description:** A 23 year old male had a six year history of recurrent attacks of gout affecting both of his knees and feet. He did not have any lifestyle risk factors or any apparent triggers. He also had psoriasis that was poorly responsive to topical treatment and psoriatic arthritis. His serum uric acid level was 724 µmol/L and previous joint aspirates demonstrated uric acid crystals. He began Allopurinol, with Colchicine, for gout prophylaxis in 2014 but struggled to take them as swallowing the tablets caused severe nausea. In 2015 his psoriasis had not responded to topical treatment. He was commenced on Methotrexate using the subcutaneous preparation in view of his difficulty swallowing tablets. However, a persistent neutropenia led to his Methotrexate, and Allopurinol, being stopped later the same year. Instead, intramuscular Depomedrone was used to gain control over his joints and skin, and soluble oral Prednisolone was used for maintenance. By the end of 2015 the corticosteroids were causing many side effects but were failing to control his gout or psoriasis. During one attack of gout he was treated with three doses of Anakinra. Anakinra was effective in settling the attack but he had another attack within weeks. The Dermatology team began Adalimumab treatment for his psoriasis, and psoriatic arthritis, in 2016 after failed treatment with Acitretin. They did not offer Ciclosporin as this can cause hyperuricaemia. Adalimumab produced a dramatic improvement in his psoriasis but his joint pain and swelling continued unabated, requiring multiple hospital admissions. In January 2017 he was admitted to hospital due to an attack of gout affecting his left knee and ankle despite taking 15mg soluble oral Prednisolone regularly. He had prominent features of Cushing's syndrome as well as tophi on both ears and a serum uric acid level of 849 µmol/L. We were reluctant to increase his Prednisolone dose further, and his response to Anakinra had been short-lived, so we gave him an intramuscular Synacthen depot which settled his joint pain and swelling very quickly. It was evident that long term gout prophylaxis was required but only Allopurinol is available as an oral suspension or liquid. Rasburicase is not routinely available for gout and was not felt to be appropriate. His neutrophil count had returned to the normal range so, after discussion with the Haematology team, the patient restarted Allopurinol using the liquid preparation with blood monitoring for neutropenia. He continued his oral prednisolone and was given a second dose of intramuscular Synacthen depot to prevent attacks whilst the Allopurinol was established. The patient continues to have some joint pains but is not experiencing attacks of gout as he had before. Overall he is feeling well. His Prednisolone dose is now 5mg and he is tolerating Allopurinol 300mg, albeit through crushing tablets, which is possible but not recommended. His serum uric acid level is now 345 µmol/L.

**Discussion:** Gout is uncommon in patients under 25 but can occur. These patients are more likely to have a family history of gout. They are also more likely to suffer recurrent attacks. Early onset of gout is associated with very high uric acid levels in the serum and urine so these patients are at greater risk of tophi and renal disease. It is therefore important that this group of patients receive optimal treatment as set out by the British Society for Rheumatology guideline for the management of gout. All the urate lowering therapies currently recommended for use in the UK are oral medications. This may exclude patients who are unable to swallow from potentially beneficial treatment. These patients could be managed symptomatically with corticosteroids which can be given by most routes. However, corticosteroids do not treat hyperuricaemia and their side effects can be prohibitive. Patients who have a poor swallow, or enteral feeding tubes, may tolerate Allopurinol in its liquid or oral suspension forms. Some Allopurinol tablets can be crushed but this is not generally recommended, and crushing is not advised for the other urate lowering therapies. Consequently, if Allopurinol is contraindicated, or if patients can only receive parenteral treatments, it may be necessary to consider Pegloticase or Rasburicase.

**Key learning points:** Our case has highlighted a number of learning points: 1. Young patients with gout often have more severe disease 2. The urate lowering therapies that have approval in the UK are all oral medications 3. Allopurinol is the only urate lowering therapy available as a liquid 4. Patients with swallowing difficulties have few treatment options for hyperuricaemia
